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Umbilical cord blood (UCB) mononuclear cells (UCBMNC) transplants improve recovery in 
animal spinal cord injury (SCI) models.  We transplanted UCBMNC into 28 people with 
chronic complete SCI in Hong Kong (HK) and Kunming (KM).  Stemcyte Inc. donated 
UCBMNC isolated from human leukocyte antigen (HLA≥4:6) matched UCB units.  In HK, four 
participants received four 4-µL (1.6 million cells) injections into dorsal entry zones above 
and below the injury site and another four received 8-µL (3.2 million cells) injections. The 8 
participants averaged 13 years after C5-T10 SCI.  Magnetic resonance diffusion tensor 
imaging of 5 participants showed white matter gaps at the injury site before treatment.  Two 
participants had fiber bundles growing across the injury site by 12 months and the rest had 
narrower white matter gaps.  Motor, walking index of SCI (WISCI) and spinal cord 
independence measure (SCIM) scores did not change.  In KM, five groups of four participants 
received four 4-µL (1.6 million cells), 8-µL (3.2 million cells), 16-µL (6.4 million cells), 6.4 
million cells plus 30mg/kg methylprednisolone (MP), or 6.4 million cells plus MP and a 6-
week course of oral lithium carbonate (750 mg/day).  KM participants averaged 7 years 
after C3-T11 SCI and received 3-6 months of intensive locomotor training.  Before surgery, 
only 2 participants walked 10 meters with assistance and did not need assistance for bladder 
or bowel care before surgery.  The rest could not walk or do their bladder and bowel care 
without assistance.  At a year (41-87 weeks), WISCI and SCIM scores improved, i.e. 15/20 
participants walked 10 meters (p=0.001); 12/20 did not need assistance for bladder care 
(p=0.001) or bowel care (p=0.002).  Five participants converted from complete to 
incomplete (2 sensory, 3 motor; p=0.038) SCI.  We conclude that UCBMNC transplants and 
locomotor training improved WISCI and SCIM. Additional clinical trials are proposed. 
Keywords: umbilical cord blood, spinal cord injury, mononuclear cells, lithium, central 
pattern generator 
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INTRODUCTION 
Umbilical cord blood (UCB) mononuclear cell (UCBMNC) transplants improve walking 
recovery in rat 1-18 and dog 19-24 spinal cord injury (SCI) models.  Investigators gave the cells 
by intravenous infusion 1,25,26, intrathecal injection 27,28, or transplantation into the spinal 
cord 3,4,6,15,21.  A few investigators used allogeneic canine 19,23,29 or fetal rat UCB 13, some 
directly infused human UCB intravenously 1,8,15 while others used human UCBMNC enriched 
for CD34+ cells 3,5-7,10,16,21,25,30-35 or CD45+ cells 28, mesenchymal cells cultured from human 
4,11,12,19,22,24,27,36-46 or canine UCB 19,23,29,47, human UCB cells selected for neural 
characteristics 48-53, somatic stem cells 18, human UCBMNC transfected to express growth 
factors 54,55, human UCBMNC combined with olfactory ensheathing glia 56 or lithium chloride 
12.  In addition, many groups studied human umbilical cord tissue-derived mesenchymal cells 
14,19,24,29,36-39,45,46,57-79  
UCBMNC may improve recovery through multiple mechanisms, including secretion of anti-
inflammatory cytokines 9,30-32, release of growth factors 8,10,11,46, upregulation of matrix 
metalloproteinases 31, downregulation of tissue plasminogen activator 32, prevention of 
apoptosis 30, facilitation of myelination 7,22,49, reduced gliosis 24,47, and increased 
angiogenesis 35.  Although several groups have claimed that UCB differentiate into neural 
precursors 80,81 or neural stem cells 82-85, none have provided convincing evidence of 
neuronal or astroglial production by UCB stem cells transplanted into animal spinal cords.   
Lithium stimulates stem cell proliferation 86, neurogenesis 87, and regeneration of long 
spinal tracts.88-90  Systemic lithium treatment increases neurotrophin expression in contused 
rat spinal cords after transplants of neonatal rat mononuclear cells, including nerve growth 
factor (NGF), neutrophin-3 (NT-3), and glial derived neurotrophic factor (GDNF) known to 
stimulate spinal axonal growth. 91   Deng, et al. 12 reported that lithium combined with 
human UCBMNC improves locomotor recovery in rats after SCI.  We therefore proposed to 
do clinical trials to assess safety and effects of lithium, UCBMNC, and UCBMNC plus lithium 
therapy of SCI. 
Copyright © 2016 Cognizant Communication Corporation 
 
CT-1483 Cell Transplantation early e-pub; provisional acceptance 03/29/2016 4 
Several groups have transplanted UCBMNC and UCB mesenchymal cells into people with SCI.  
In 2005, Kang, et al. 92 reported hip and thigh movement recovery after transplanting human 
leukocyte antigen (HLA) matched UCB “multipotent stem cells” into the spinal cord of a 37-
year old woman with chronic SCI.  In 2010, Ichim, et al. 93 transplanted UCBMNC into the 
spinal cord of a patient with chronic SCI.  In 2011, Cordes, et al. 94 transplanted human 
CD34+ UCB cells into spinal cord of a patient with amyotrophic lateral sclerosis.94  In 2013, 
Yao, et al. 96 reported improved autonomic function and somatosensory evoked potentials 
12 months after intrathecal and intravenous injection of UCBMNC into 25 patients with 
chronic SCI (>6 months).  Several groups have transplanted umbilical cord mesenchymal 
cells 97-100 intrathecally into patients with SCI.   Except for the two case reports, none of the 
trials transplanted UCBMNC directly into the spinal cord.   
We did Phase I and II clinical trials in Hong Kong (HK) and Kunming (KM) to assess the 
safety and efficacy of transplanting escalating doses of HLA-matched (≥4:6) UCBMNC into 
spinal cords of people with chronic (1-19 years after) complete C5-T11 SCI.  The phase I trial 
in HK transplanted 1.6 or 3.2 million UCBMNC into spinal cord above and below the injury 
site.  The patients (average 13 years after injury) did not receive any walking training and 
we did magnetic resonance diffusion tensor imaging (MR-DTI) to visualize long spinal tracts.  
The phase II trial in KM randomized 20 patients with chronic (average 7 years after) 
complete C5-T11 SCI to five treatment groups receiving 1.6, 3.2, or 6.4 million UCBMNC, 6.4 
million UCBMNC with a 30-mg/kg bolus dose of methylprednisolone (MP), or 6.4 million 
UCBMNC with MP and a 6-week course of oral lithium carbonate.  In KM, the patients 
started 3-6 months of intensive locomotor training and were assessed at 6 weeks, 3 months, 
6 months, and one year after surgery for changes of American Spinal Injury Association and 
International Spinal Cord Society (ASIA/ISCOS) impairment scale (AIS) classification, motor 
and sensory scores, the walking index of spinal cord injury (WISCI), the spinal cord 
independence measures (SCIM), modified Ashworth scale (MAS) for spasticity, visual analog 
scale (VAS) for pain, and severe adverse events (SAE).   
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MATERIALS AND METHODS 
Inclusion and exclusion criteria.  The trials included male and female adults (18-60 years 
old) with chronic (≥1 year), neurologically stable (≥6 months), C5-T11 neurological levels, 
and complete (ASIA/ISCOS Impairment Scale or AIS A) SCI.  We excluded people who were in 
another trial within 4 weeks, who had surgical or medical risks, or who were pregnant or 
lactating. 
Treatments.  Participants were assigned sequentially to five treatment groups:  Group A 
received four 4-µL injections of UCBMNC (100,000 cells/µL), Group B received four 8-µL 
injections, Group C received four 16-µL injections, Group D received 16-µL injections plus a 
30mg/kg intravenous bolus of methylprednisolone sodium succinate (MP), and Group E 
received four 16-µL injections plus MP and a 6-week course of oral lithium carbonate (750 
mg/day).  In HK, 8 participants were assigned to only groups A and B (n=4/group).  In KM, 
20 participants were assigned to all 5 groups (n=4/group) and received intensive locomotor 
training for 6 hours/day, 6 days/week, and for 3-6 months. 
The primary outcome measure was ASIA/ISCOS motor and sensory scores 101,102.  
Secondary outcomes include ASIA/ISCOS Impairment Scale (AIS), Walking Index of Spinal 
Cord Injury or WISCI 103, Spinal Cord Independence Measure or SCIM 104, Modified 
Ashworth Scale or MAS for spasticity 105, Visual Analog Score or VAS for pain 106.  We 
categorized adverse events by severity, relevance, significance, and outcomes.  
Adverse Events, Neurological, and SCIM Assessment.  The surgical teams reported 
adverse events, judging severity and relevance of the events.  At 6 weeks, 6 months, and one 
year after surgery in HK, a rehabilitation team consisting of physical therapist and an 
occupational therapist assessed the patients under the supervision of an orthopedic 
surgeon and head of the spinal rehabilitation team.  In KM, a team of doctors and nurses 
evaluated the patients. All examinations were videotaped.  The China Spinal Cord Injury 
Network staff monitored the trials and data collection of both trials. 
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Unit Selection.  Frozen plasma-depleted UCB units were donated by Stemcyte Inc. (Covina, 
CA) and processed for mononuclear cells by Vista Biologics (Carlsbad, CA).  We selected units 
from by matching human leukocyte antigens (HLA≥4:6), initially low-resolution A, B, and DR 
and confirmed by medium (HLA-A and B) to high-resolution (HLA-DR) typing after 
transplantation.  All units fulfilled National Marrow Donor Program (NMDP) standards for 
UCB transplantation.107  Units from donors who may have had hepatitis B (e.g. positive 
maternal antibody) were excluded.   
Cell Preparation. Vista Biologics (Carlsbad, California) prepared the cells for transplantation.  
Each frozen cord blood unit was thawed at 4˚C, washed to reduce dimethylsulfoxide (DMSO) 
concentration from 10% to <1%, treated with human DNAase (Pulmozyme, Genentech), and 
centrifuged in a Ficoll Hypaque (GE Healthcare Life Science, 1.077 specific gravity gradient) 
to isolate the UCBMNC.  The cells were suspended (1 million cells/ml) in animal product-free 
CO2-independent media (Invitrogen, CA) and shipped at 12-28˚C.   We shipped 38 test units 
from Carlsbad to Hong Kong and Kunming.  About 10% of UCBMNC were lost per day of 
shipment.  Shipping at room temperature enriched the UCBMNC for monocytes (35-45%), 
CD34+ or CD133+ cells (3-4%), nucleated red cells (1-2%), and mesenchymal (CD105 ~1%) 
cells.   
Transplantation.  Upon arrival at hospital, the cells were washed in saline, a small aliquot 
was removed to count cells that excluded trypan blue dye, and the remaining cells were 
suspended in normal saline containing 1% human albumin (CSL, Australia) so that each µL 
has ~100,000 trypan-blue excluding mononuclear cells.  The cells were loaded into a 27-
gauge (27G x ¾” or 0.4 x 19 mm, EXEL INT Sterile Scalp Vein Set) needle attached to a 100-
µL Hamilton syringe with flexible tubing.  After laminectomy, durotomy, and removal of 
adhesions between spinal cord and surrounding tissues, the surgeons manually inserted the 
needle 3 mm deep at a 45˚ angle (bevel up) into left and right dorsal root entry zones (DREZ) 
at 5 mm above and 5 mm below the injury site, and slowly (1 µL/minute) injected 4, 8, or 16 
µL of cell suspension into each of the 4 sites.  The dura was sutured to prevent 
cerebrospinal fluid leak.  Postoperative care included analgesia and antibiotics as necessary.     
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Magnetic Resonance Imaging and Diffusion Tensor Imaging.  In HK, we used a 3-Tesla 
magnetic resonance imaging (MRI) scanner (Achieva X-series, Phillips Healthcare, the 
Netherlands) to obtain diffusion tensor images (DTI) of the spinal cord.  Conventional MRIs 
were first obtained (3D T2W and T2W) to locate the injury site.  Fiber tracts were selected 
for tractography by manually identifying regions of interest (ROI) above the injury site for 
descending fibers and below the injury site for ascending fibers.  Using software purchased 
from the manufacturer (Phillips Healthcare), we first quantified the fractional anisotropy of 
the selected ROI, yielding ratios that indicated the degrees to which diffusion of water is 
anisotropic, calculated with eigenvaleus (λ1, λ2, λ3…) of the diffusion tensor.   
Initial scans were obtained from six volunteers without spinal cord injury (six of the 
investigators volunteered).  The FA values of normal spinal cords were quite reproducible, 
ranging from 0.65 to 0.55 from C1 through T12, declining in the more distal segments.  
Standard errors of average FA values were usually ±0.05, suggesting that the measurements 
are reproducible.  In addition, we did MR-DTI scans of seven people with complete spinal 
cord injury (SCI) who did not receive surgery or cell transplantation.  Every one had a gap at 
the injury site.  One person was recruited to be part of the trial but we unfortunately could 
not find a suitable 4:6 HLA match.  The participant agreed to have followup MR-DTI and the 
gap was unchanged 2 years later. 
Clear and distortion free DTI images were obtainable from only 5 of the 8 participants in the 
HK trial.  In three participants, distortion from fixation instruments was too great to allow 
the tractography.  Once a set of MR-DTI parameters were determined for a satisfactory DTI 
in a participant, further scans on the participant were done with the same parameters, so 
that the images could be compared over time.  Three participants agreed to have followup 
scans at 1.5 years after surgery and one participant was rescanned at 2 years.  We 
compared the white matter gap in DTI images obtained before treatment and at one year or 
later in three participants.  Two participants showed evidence of long bundles crossing the 
injury site and growing progressively into proximal and distal spinal cord over time.   
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Locomotor Training.  In HK, the clinical trial participants did not receive locomotor training.  
In KM, at 14 days after surgery, the participants started locomotor training according to the 
Kunming locomotor scale (KLS) described earlier 108.  The participants initially stood with 
help (KLS II), then without help (KLS III), walked in a rolling walker with minimal (KLS IV) 
or no assistance (KLS V), or walked with a 4-point walker (KLS VI) without assistance.  
Participants walked as much as 6 hours a day and 6 days a week for 3-6 months.  They 
typically walked 3 hours in the morning and 3 hours in the afternoon.  The participants left 
hospital at 3 or 6 months, the latter if they were still improving at 3 months. One-year 
followup ranged from 41-87 weeks (41-87w).   
Statistical Analyses.  We used IBM SPSS Statistics (version 22) to do repeated measures 
analysis of variance (ANOVA) to assess ASIA, SCIM and VAS score changes over time (Time) 
and treatments groups (Group), the Kruskal-Wallis test to compare AIS, MAS, WISCI, and 
KLS among treatment groups, and Wilcoxon signed-rank test to compare AIS, MAS, WISCI 
and KLS before and 41-87w after treatment, and Spearman correlation to relate KLS and 
WISCI. Missing data were assumed to equal the last observation, i.e. last observation carried 
forward (LOCF).  To assess WISCI score changes (∆WISCI) and HLA-matching, we used 
ANOVA and Scheffés post hoc test (Statview) and the Chi-Square contingency test (Prism 6, 
GraphPad Software).  We used the Chi-Square test to assess HLA-matching among treatment 
groups.  All ±values indicate standard errors, P-values of <0.05 were considered significant, 
and analyses were based on intention-to-treat. 
Consent, Approvals, and Registrations.  Each participant gave informed consent. 
Institution review boards of the Chinese University of Hong Kong and University of Hong 
Kong approved the trial and the Hong Kong Department of Health approved the trial.  The 
Ethics Committee of Kunming People’s Liberation Army Hospital of Chengdu Military 
Command approved the trial.  Western IRB (Seattle, WA) gave an “approvable” rating for 
both trials. The Military Medical Ministry and Yunnan Department of Science and Technology 
awarded grants for the KM trial.  The two trials were registered on 
https://www.clinicaltrials.gov as NCT01046786 and NCT01354483. 
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RESULTS 
Participants.  Eight people (1 female, 7 males) participated in HK and 20 people (4 females, 
16 males) participated in KM.  At enrollment, the ages of participants averaged 42.6±2.7 
(range 29-53) in HK and 36.9±2.4 (18-53) years old in KM, respectively 12.8±2.6 (2-20) and 
7.2±1.2 (2-20) years after injury.  All 8 participants in HK were “complete” (AIS A) with C5-
T10 neurological levels and 19/20 participants in KM were AIS A with C5-T11 neurological 
levels and one was sensory incomplete (AIS C) with C3 neurological level.  Figures 1 and 2 
summarize the HK and KM data.  All had significant spinal fractures and most had metallic 
implants to stabilize the spinal fractures.  In HK, all participants had WISCI scores of 0.  In 
KM, 2 participants had WISCI scores of 2 before treatment.  
Treatments. Cord blood units were selected based on low-resolution HLA matching 
(HLA≥4:6) for HLA-A, -B, and –DR and then checked for medium (HLA-A and –B) and high 
resolution (-DRB1) matching after transplantation.  In HK, 2 participants matched 6:6 and 
six matched 5:6 at low resolution but subsequent medium-high resolution matching showed 
one participant matching at 6:6, one at 5:6, and six at 4:6.  In KM, 6 participants matched 6:6, 
ten 5:6, and four 4:6 at low resolution and subsequent medium-high resolution matching 
showed 9 participants matching at 5:6, seven at 4:6, three at 3:6, and one at 1:6.  Low-
resolution HLA matches differed among KM treatment groups (X2=15.67, df=8, p=0.0474) 
but medium-high resolution matches did not (X2=13.17, df=12, p=0.3565). All participants 
received planned doses of cells.  One Group E participant (#18) received placebo instead of 
lithium.  Three KM participants did not complete locomotor training, two due to possible 
tibial fractures (#2, #8) and one due to knee swelling (#20). 
Diffusion Tensor Imaging.  All MR-DTI showed gaps at the injury site (Figure 3).  At 6-18 
months, two participants had progressive fiber growth crossing the gap.  Figure 4 shows 
pre-treatment, 6-month, and 1-year MR-DTI of a participant with T4 SCI.  Figure 5 shows 
MR-DTI’s of an uninjured spinal cord, spinal cords with narrow and wide gaps, fibers 
crossing the gap, and 2 spinal cords with narrower gaps at 12 months after transplantation.  
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Adverse Events.  Nine adverse events occurred in 3 participants in HK.  One participant 
developed neuropathic pain (probably related), hyperthyroidism (probably unrelated), and 
hypertension (probably unrelated).  A second participant developed a thin subdural 
hematoma and pneumocephalus due to cerebrospinal fluid (CSF) loss during surgery.  He 
also developed back sore.  Both resolved spontaneously.  A third participant developed 
subarachnoid hemorrhage (definitely related), neuropathic pain (probably related), and 
colon cancer (not related); the first two resolved spontaneously.  In KM, 68 adverse events 
occurred in 19 participants: 43 were unrelated, 17 definitely, 1 probably, and 7 possibly 
related to treatment.  The most common event was post-operative wound swelling and pain 
in 9 participants.  All adverse events resolved with routine therapies.  No patient had 
neurological loss.  In the 28 participants in the two trials, 5 had serious adverse events (SAE).  
One participant (Group A K1) had slow wound healing and low serum protein; both 
resolved on a high protein diet.  Another  (Group A K2) developed a CSF leak and wound 
dehiscence that required re-operation.  He was later found to have an old tibial fracture and 
stopped locomotor training. A third (Group A H2-2) had blood pressure increase requiring 
hospitalization.  A fourth (Group C, K12) had left leg swelling and thrombosis of vena iliaca 
externa treated by vena cava filter (unrelated).  A fifth participant (Group B H1-3) had colon 
adenocarcinoma discovered at 21 months (probably unrelated).   
Spasticity and Pain.  In HK, the 8 participants had no or mild spasticity before and after 
treatment.  Three had severe neuropathic pain (VAS>50) before treatment that decreased 
(88 to 76, 51 to 28, 67 to 0) after treatment and two developed neuropathic pain after 
treatment (0 to 62, 12 to 24).  In KM, 5 participants had mild spasticity (MAS=1) and 2 had 
moderate spasticity (MAS=2) before treatment; at 41-87w, 7 participants had 1-point 
increases of MAS scores while 2 participants had 1-point decreases, not significant 
(X2=2.977, df=4, p=0.562).  Before treatment, 5 participants had VAS scores of 12-50 out of 
100.  Between w0 and 41-87w, VAS score increased in 3 participants (range: +15 to +69) but 
decreased in 4 participants (range -5 to -43), not statistically significant (Time: F=0.015, 
df=1, p=0.905; Group: F=0.0470, df=4, p=0.757; Group•Time: F=1.232, df=4, p=0.339).   
Two participants in Group E had high VAS scores; lithium reduced VAS scores in both. 
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ASIA Grade, Levels, and Scores.  In HK, 1 of 8 participants (7%) converted from AIS A to B, 
4 gained 2-5 points in touch scores, and 2 had 2-3 point motor score increases.  In KM, 2 
participants switched from AIS A to B (10%) and three from AIS A to C (15%). Neurological 
levels descended one segment in 6 participants (30%).  Ten participants (50%) gained 1-10 
touch points and 9 (45%) gained 1-8 pinprick points between w0 and w41-87. Mean 
sensory scores increased over time, i.e. touch scores increased 1.7 points (Time, F=9.869, 
df=1, p=0.007; Group, F=0.346, df=4, p=0.299; Group•Time, F=0.535, df=4, p=0.712) and 
pinprick scores increased 2.6 points (Time, F=8.984, df=1, p=0.009; Group, F=8.984, df=4, 
p=0.284; Group•Time, F=0.455, df=4, p=0.768).  Motor scores did not change significantly 
(Time: F=1.800, df=1, p=0.200; Group: F=0.145, df=4, p=0.962; Group•Time: F=0.800, df=4, 
p=0.544), one participant gained 2 and another gained 4 points.  
Locomotor Training.  Participants in HK did not receive locomotor training.  In KM, 17 of 
20 participants received intensive locomotor training.  Before treatment, 4 participants could 
not stand (KLS I), fifteen needed help to stand (KLS II), and one walked in a rolling walker 
with minimal assistance (KLS IV), i.e. an assistant pulled on ropes to stabilize knees during 
walking.  By w14-24, 17 of 20 participants (85%) were training at KLS IV (figure 6).  Nine 
participants went home at 14 weeks because they reached a plateau (n=6) or stopped 
training (n=3) due to tibial fractures in two cases or swollen knee in one case. After going 
home, four participants did not continue walking and regressed.  At 41-87w, only thirteen 
(65%) walked at KLS IV and two (10%) walked unassisted with 4-point walkers (KLS VI).  
KLS at 41-87w differed significantly from w0 (Z=3.532, p<0.0005).   
Walking Recovery.  In HK, no participants walked before or after treatment.  In KM before 
treatment, 16 participants (80%) could not walk (WISCI 0), one walked <10m (WISCI 1), 
one walked 10m (WISCI 2) in parallel bars with braces and 2 assistants, and two walked 
10m in a walker with braces and no assistants (WISCI 9).  At 41-87w, 5 participants had 
WISCI 0, two were WISCI 2, six (30%) walked 10m with one assistant (WISCI 6), and seven 
(35%) walked without assistance (WISCI ≥7).  WISCI scores at 41-87w differed from W0 
(Z=3.315, p=0.001). WISCI and KLS correlated highly (r=0.925, p<0.0005). 
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SCIM Scores.  The SCIM has 19 subscores covering self-care, respiration and sphincters, 
and mobility.  In HK, SCIM scores did not change significantly. In KM, most participants 
increased their SCIM scores.  Repeated measures ANOVA confirmed that mean SCIM scores 
increased over time (F=51.194, p<0.0005) by 19.6±2.67 points between w0 and 41-87w.  
Fourteen of 19 SCIM subscores, i.e. except feeding, grooming, respiration, outdoors mobility 
(>100m) and stair management, improved significantly between w0 and 41-87w (Figure 7-
8).  The self-care subtotal score accounted for 3.6 points while the respiration and sphincter 
subtotal accounted for 9.7 points, and the mobility subtotal accounted for 6.3 points.  The 
bladder, bowel, and toilet subscores accounted for almost half of the SCIM score 
improvement.  At w0, 2 (10%) participants were independent for bladder and bowel care but 
twelve (60%) became independent by 41-87w.   Two (10%) participants were catheter-free 
at w0 but ten (50%) were catheter-free at 41-87w.  Bowel care subscores indicate that 12 
(60%) participants did not require assistance for bowel procedures at 41-87w, compared to 
2 participants before treatment.  Likewise, 65-70% of participants could transfer from bed to 
wheelchair and from wheelchair to toilet and tub at 41-87w, compared to 5-30% at w0. At 
41-87w, 35% of participants could walk without assistance or supervision indoors and for 
moderate distances up to 100m.  For distances >100m, only 2 participants walked and the 
rest used wheelchairs.  Table 1 shows means and standard errors of total SCIM and 
subscores, as well as t-values, Wilcoxon Z values, and p-values.  
Treatment Effects.  Comparison of walking scores among the treatment groups revealed 
that all 8 participants in group B and C showed improvement of WISCI scores by 6 points or 
greater.  Only 2 participants showed improved walking in groups A and D, and only 1 
participant in group E.  Although this was not statistically significant, the data does not 
support beneficial effects of MP or lithium.  Almost every participant except for one in 
Group B showed improved SCIM scores.  Severe adverse events (SAE) did not differ amongst 
the groups, occurring in four of the five treatment groups, with two in Group A, one in Group 
B, one in Group C, and one in Group D.  Figure 9 shows the ANOVA of change of WISCI 
scores in the five treatment groups.  Mean change of WISCI scores increased from 3.5 to 6.1 
to 9.1 in Groups A, B, and C, fell to 2.9 in Group D, and fell to 0.4 in Group E.   
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Discussion 
The HK trial showed that 4-8 µL of UCBMNC can be safely injected into spinal cord above 
and below the injury site.   MR-DTI suggest that white matter gaps decreased at the injury 
site and two participants showed bundles of fibers growing across the injury site into 
surrounding spinal cord at 6-18 months.  However, the participants did not recover motor 
function.  The KM trial showed that 4, 8, and 16 µL of UCBMNC can be safely injected into 
the spinal cord.  Over half of the participants recovered walking with minimal or no 
assistance by 6-12 months after UCBMNC transplants and locomotor training, as well as 
increased independence in activities of daily living, including self-care, bowel and bladder 
function, and mobility.   This is an unprecedented recovery for complete chronic SCI. 
Walking recovery is rare in patients with chronic complete SCI 109-111.  The finding that 
15:20 participants (75%) with chronic complete SCI could walk 10m and seven (35%) 
walked 10m without manual assistance a year after treatment is unprecedented. SCIM 
indoor mobility subscores confirmed that 7 participants (35%) walked indoors without 
assistance at one year after treatment.  Likewise, mobility subscores for moderate distances 
showed the same 7 participants (35%) walking 10-100m without assistance, 2 (10%) 
walking with supervision, and the rest using wheelchairs.  For distances of >100m, only 2 
participants (10%) walked while the rest used wheelchairs.  Thus, 35% of participants used 
walking for indoors and for moderate distances <100m but most participants preferred 
wheelchairs for longer distances >100 m.   
Late conversions from AIS A to B or C are also rare.  As Kirschblum, et al. 112 pointed out, 
among 987 patients who were neurologically complete (AIS A) at one year, only 3.5% 
improved to AIS B and 1.05% improved to AIS C and D by 5 years.  In HK, 1 of 8 participants 
converted from AIS A to B (12.5%).  In KM, 2 participants converted from AIS A to B (10%) 
and three from AIS A to C (15%), a conversion rate of 25%. These changes were statistically 
significant (Z=2.070, p=0.038) but did not vary among treatment groups. 
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SCIM scores indicated significant improvements in independence for bladder function.  
Before treatment, 18 participants (90%) required assistance for bladder care and 15 
participants (75%) used catheters.  At w14-24, 16 participants (80%) were still 
catheterizing.  At 1 year after treatment, 12 (60%) participants did not need assistance for 
bladder care and 11 participants (55%) no longer used catheters.  Three participants (15%) 
did not use catheters or drainage devices. 
Bowel function also improved.  Before treatment, 6 participants (30%) had irregular or low 
frequency bowel movements (<1/3 days) and 90% required assistance.  By discharge from 
hospital at 14-24 weeks, all participants became regular but 75% still needed assistance and 
had occasional accidents.  By 41-87w, however, 60% did not require assistance and rarely 
had accidents.  Four participants (20%) had no accidents.   We plan to bring the participants 
back for further evaluation. 
MP and lithium may have reduced walking recovery.  Animal studies suggest that MP 
improves survival of transplanted cells 113 and lithium should improve walking recovery 90 
after acute SCI.   Only 2 of 8 participants (25%) in Groups D (6.4 million cells plus MP) and E 
(6.4 million cells plus MP and lithium) recovered walking to 6 points on WISCI, compared to 
8 of 8 participants (100%) in Groups B (3.2 million cells) and C (6.4 million cells).  Lithium 
reduced neuropathic pain in two participants in Group E, consistent with our earlier report 
that lithium reduces neuropathic pain.114  
Change in WISCI scores (∆WISCI) increased with cell dose.  As Figure 9 shows, ANOVA of 
∆WISCI in the five treatment groups showed progressive increase in ∆WISCI in Groups A, B, 
and C but ∆WISCI decreased in Groups D and Group E.   Post hoc tests (Scheffés) suggest 
that Group C and E differed significantly at p<0.0051.  However, one patient (#18) in Group 
E inadvertently received placebo rather than lithium tablets, one patient (#19) was already 
walking at WISCI 9 when the trial began, and one patient (#20) stopped walking training 
due to knee swelling.  Thus, only one patient in Group E represented a valid comparison 
with Group C.  Further clinical trials are needed to determine whether lithium is effective.   
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Two other findings are noteworthy in the KM trial. First, two participants had to discontinue 
locomotor training due to old bone fractures.  We should screen participants in future trials 
for old bone fractures.  Second, many participants did not show improved motor scores 
despite recovering walking and other programmed spinal cord functions, i.e. micturition 
and defecation.  We hypothesize that UCBMNC transplants stimulated growth of axons that 
activate lumbosacral central pattern generators for walking, micturition, and defecation but 
only in participants who received intensive locomotor training. 115   This would explain why 
most patients could walk but could not voluntarily contract individual muscles or feel specific 
sensory signals in their legs at one year after treatment.  It is possible that some patients will 
recover more voluntary motor and sensory function later. 
Our trials left several critical questions unanswered.  First, can intensive locomotor training 
alone improve locomotor function in people with chronic complete SCI?  Several years ago, 
most doctors would have replied that locomotor training alone cannot restore locomotion to 
people with chronic complete SCI.  Second, does untethering surgery improve the effects of 
intensive locomotor training?  In our trials, all patients that received transplants also received 
untethering surgery.  Many neurosurgeons 116-131 have reported beneficial effects of 
untethering surgery in patients with spina bifida or syringomyelic cysts.   Third, does lithium 
improve locomotor recovery when combined with UCBMNC and intensive locomotor 
training?  We 114 have previously observed that a 6-week course of lithium does not improve 
motor or sensory function in patients with chronic complete SCI but these patients did not 
receive any locomotor training.  If lithium does not improve function when combined with 
UCBMNC and locomotor training, we should exclude it from future phase III trials.   
We have proposed further phase II trials to answer these questions.  The first trial will 
ascertain whether locomotor training alone or untethering surgery plus locomotor training 
restore walking in people with chronic complete SCI.   This trial (NCT02663310, 
http://clinicaltrials.gov) is underway in Kunming, comparing walking outcomes of 30 people 
with chronic complete SCI, randomized to untethering surgery or no surgery, followed by 6 
months of intensive locomotor training.   We have applied for two phase II trials, one in India 
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and the other in the United States, to ascertain whether lithium improves locomotor 
recovery of participants with chronic SCI, randomized to UCBMNC transplants or UCBMNC 
plus a 6-week course of lithium, followed by 6 months of intensive locomotor training.   
These trials will provide the following important information needed for design of pivotal 
phase III trials of UCBMNC treatment.  First, if the trials show no significant benefits of 
adding lithium to UCBMNC transplants, lithium should be omitted from the phase III trials.  
Second, if locomotor training alone or untethering surgery plus locomotor training improves 
walking recovery in patients with chronic complete SCI, it would provide justification for a 
surgery control group involving untethering only.  Finally, intensive locomotor training (6 
hours a day, 6 days a week for 6 months) has not been practiced outside of Kunming.  It is 
important to establish that such training is feasible elsewhere since our trials to date suggest 
that intensive locomotor training is essential for recovery of walking. 
In summary, our data indicate that UCBMNC can be safely transplanted into the spinal cord 
of people with chronic SCI, intensive locomotor training is essential for motor recovery, and 
UCBMNC transplants combined with intensive locomotor recovery can lead to significant 
locomotor, bowel, and bladder recovery in people with chronic complete SCI.  However, the 
patients did not recover much voluntary motor function.  Some participants recovered 
sensory dermatomes close to the injury site and as many as a quarter of the patients 
recovered anal sensation and voluntary sphincter contraction, converting from AIS A to B 
and C.   Further clinical trials are necessary to determine whether these improvements are 
due to UCBMNC, untethering surgery, or intensive locomotor training.   
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Figure 1.  Neurological levels and scores in Hong Kong (HK).  Each column represents 
a participant in the trial:  dark green indicates segments with normal sensation and 
motor function, dark green with white letters indicates the neurological level before 
treatment, red with white letters indicates changed neurological level one year after 
treatment, light green indicates zone of partial preservation (ZPP) before treatment, 
and pink indicates ZPP after treatment.  Individual participant data are listed, 
including age and years after injury, sex, medium-high resolution (medium for HLA-A 
and –B and high for HLA-Dr) HLA matches out of 6.  AIS is ASIA:ISCOS Impairment 
Scale where A is complete, B is sensory incomplete, and C is motor incomplete that 
<50% of motor score in the legs. None of the participants received walking training 
or recovered walking; hence, no Kunming Locomotor Scores (KLS) or Walking Index 
of Spinal Cord Injury (WISCI) scores are listed.  Motor score is the sum of muscle 
grades (0-5) for ten muscles on each side of the body, totaling 100 points.  Touch and 
Pin refer to light touch and pinprick scores (0=no, 1=abnormal, 2=normal) for 28 
dermatomes on each side of the body.  MAS is modified Ashworth scale (0-4) for 
spasticity.  VAS is visual analog scale (0-100) for pain.  SCIM is spinal cord 
independence measure (0-100).  Red indicates improvement.  SAE (yellow) refers to 
severe adverse events. 
Figure 2.  Neurological levels and scores in Kunming (KM).  Each column represents a 
participant in the trial.  The color columns indicate the neurological level (green) at 
the time of treatment, improvements in neurological level (red), and improvements in 
ZPP or zones of partial preservation (pink), light green indicates ZPP before 
treatment. Two participants converted from complete to sensory incomplete, 3 
participants were converted to motor incomplete (AIS C).  Five participants had 
adverse events:  WH = wound healing, TF = tibial fracture, KS = knee swelling.  See 
legend for figure 1 for explanation. 




Figure 3.  A magnetic resonance diffusion tensor image (MR-DTI) of the spinal cord 
before treatment. White matter tracts were selected from regions of interest (ROI) 
above the below the injury site and tract-tracing software was then used to identify 
adjacent pixels with similar diffusion tensors.  Descending tracts are colored purple 
and green while ascending tracts are colored blue.  A clear gap was present in the 
spinal cord at C6 vertebral level.   
Figure 4.  Magnetic resonance diffusion tensor images (MR-DTI) of the spinal cord 
of a participant before operation (Pre-op), at 6 months (6m), and 12 months (12m) 
after treatment.  Before operation, MR-DTI showed very atrophic descending fibers 
(blue), more ascending fibers (green), and a clear gap at the T4 injury site.  At 6 
months, the gap was still present.  At 12 months, both ascending and descending 
fibers were crossing the gap (upper right).  On the lower right image, ascending 
fibers (dark blue) were removed so that the descending fibers (light blue) could seen 
to extend into the lumbosacral spinal cord. 
Figure 5.  Magnetic resonance diffusion tensor images (MR-DTI) of a normal 
cervical spinal cord (A), an image of an injured spinal cord with a narrow gap before 
treatment (B), an image of an injured spinal cord with a wide gap before treatment 
(C).  D, E, and F show MR-DTI from a participant before, 6 months after, and 1.5 years 
after treatment.  Note the fibers crossing the gap.  G, H, I, and J show MR-DTI from a 
participant before, at 6 months, 1 year, and 2 years after treatment.  Note the 
narrowing of the white matter gap. 
Figure 6.  Kunming Locomotor Scale (KLS) and Walking Index of Spinal Cord Injury 
(WISCI).  KLS represents locomotor training stages: I indicates inability to stand, II is 
standing with assistance, III is standing without assistance, IV is walking in rolling 
walker with minimal assistance, V is walking in rolling walker without assistance, VI 
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is walking in four-point walker without assistance.  No participant trained with 
crutches (VII), cane (VIII), or without devices (IX, X).  WISCI reflects ability to 
ambulate 10 meters (10m) with devices, braces, and assistants: 0 indicates inability 
to stand or to participate in assisted walking; 1 is ambulating <10m and 2 is 
ambulating 10m in parallel bars with braces and 2 assistants; 3 is ambulating 10m in 
parallel bars with braces and 1 assistant; 4 is ambulating 10m in parallel bars with no 
braces and 1 assistant; 5 is ambulating 10m in parallel bars without braces or 
assistant; 6 is ambulating 10m with a walker with braces & 1 assistant; 7 is 
ambulating 10m with 2 crutches, braces, & 1 assistant; 8 is ambulating 10m with 
walker, no braces, and 1 assistant; 9 is ambulating in a walker with braces and no 
assistant; 10 is ambulating with 1 cane or crutch, no braces, and 1 assistant; 11 is 
ambulating with 2 crutches, no braces, and 1 assistant; 12 is ambulating with 2 
crutches, braces, and no assistant; 13 is ambulating in a walker without braces or 
assistants.  No participant achieved WISCI scores higher than 13.   Missing w24 data 
were assumed to equal w14 data and w48 refers to 41-87w.   
Figure 7.  Spinal Cord Independence Measure (SCIM) mobility scores.  Indoor 
(indoor mobility on even surfaces), Moderate Distances (10-100m) and Outdoors 
(>100m):  0 = total assistance, 1 = electric wheelchair or manual assisted wheelchair, 
2 = moves independently with manual wheelchair, 3 = walks with supervision, 4 = 
walks with walking frame or crutches by swinging, 5 = walks with crutches or two 
canes with reciprocal gait, 6 = walks with one cane, 7 = needs leg orthosis only, 8 = 
walks without walking aids.   StairMgt (go up or down stairs):  0 = total assistance, 1 
= ascends and descends ≥3 steps with support or partial assistance, 2 = ascends and 
descends at least 3 steps with rail, crutch, or cane, 3 = ascends and descends at least 3 
steps without support or supervision.  Bedmobility (turn in bed and actions to 
prevent pressure sores):  0 = total assistance to turn and to sit up in bed, to push up 
in wheelchair, with or without adaptive devices, 1 = performs one of the above 
actions without assistance, 2 = performed 2-3 of above without assistance, 3 = 
independent.  GroundWheelchair (get into wheelchair from the ground):  0 = total 
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assistance, 1 = transfers independently with or without adaptive devices. 
Figure 8.  Spinal Cord Independence Measure Toilet and Transfer Functions.  Bladder:  
0 = indwelling catheter, 3 = residual urinary volume (RUV) >100ml with assisted 
catheterization, 6 = RUV <100ml with intermittent self-catheterization (ISC) and 
external drainage (ED) with assistance, 9 = ISC and ED without assistance, 11 = ISC 
without ED, 13 = RUV <100ml, only ED and no assistance; 15 = RUV <100ml, no ED.  
Bowel:  0 = irregular or very low frequency movements <1/3 days, 5 = regular, 
requires assistance for suppositories, rare accidents <2/month, 8 = regular without 
assistance, rare accidents, 10 = regular, no assistance or accidents.  Toilet:  0 = total 
assistance, 1 = partial assistance, does not clean self, 2 = partial assistance, cleans self, 
4 = independent but requires adaptive device, 5 = independent without adaptive 
devices.  WheelchairToilet (transfers to and from toilet, locking wheelchair, lifting 
footrests, removing and adjusting armrests): 0 = total assistance, 1 = partial 
assistance or supervision, 2 = independent.  Bedwheechair (transfers from bed to 
wheelchair):  0 = total assistance to lock wheelchair, lift footrests, remove and adjust 
arm rests, transferring, lifting feet, 1 = partial assistance or supervision and/or 
adaptive devices, 2 = independent or does not require wheelchair.   WheelchairCar 
(approach a car, lock wheelchair, remove arm and footrests, transfers to and from car, 
bring wheelchair into and out of car):  0 = total  assistance, 1 = partial assistance or 
supervision/adaptive devices, 2 = independent.  
Figure 9.  Analysis of Variance (ANOVA) of change of WISCI (Walking Index of Spinal 
Cord Injury) between week 0 and week 48.  The ANOVA table indicated an F-value of 
6.765 (p=0.0026) amongst treatment groups (Rx).  The lower left graph shows means 
and standard errors of mean.  Group A received the lowest dose of 1.6 million cells, B 
received a higher dose of 3.2 million, Group C-E received the highest dose of 6.4 
million, Group D received the highest cell dose plus 30 mg/kg methylprednisolone 
(MP), and Group E received the highest cell dose plus MP and a 6-week course of oral 
lithium carbonate.  
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Table 1.  SCIM Scores and subscores 
Dependent Variable Max W0±sem (CI 95%) W48±sem (CI 95%) Δ±sem 




t p Z p 
SCIM Total 100 41·0±3·0 (34·7-47·3) 60·6±3·6 (52·9-68·2) 19·6±2·7 7.330 0.000 3.912 0.000 
SCIM Self Care 20 11·9±1·4 (8·87-14·8) 15·4±1·4 (12·4-18·4) 3·6±0·8 4.440 0.000 3.305 0.001 
  1· Feeding 3 2·5±0·2 (2·14-2·86) 2·6±0·2 (2·34-2·96) 0·2±0·1 1.143 0.267 1.134 0.257 
  2. A. Bathing (upper) 3 1·8±0·2 (1·36-2·34) 2·4±0·2 (1·96-2·94) 0·6±0·2 3.040 0.007 2.521 0.012 
      B. Bathing (lower) 3 0·8±0·2 (0·28-1·32) 1·8±0·3 (1·20-2·40) 1·0±0·4 3.979 0.001 2.976 0.003 
  3. A. Dressing (upper) 4 2·8±0·4 (2·05-3·55) 3·3±0·3 (2·67-3·93) 0·5±0·2 2.236 0.036 2.041 0.041 
      B· Dressing (lower) 4 1·6±0·4 (0·78-2·85) 2·7±0·4 (1·81-3·49) 1·0±0·5 2.761 0.012 2.395 0.017 
  4. Grooming 3 2·3±0·3 (1·75-2·85) 2·6±0·2 (2·11-2·99) 0·3±0·1 2.032 0.056 1.890 0.059 
SCIM R & S 40 18·8±1·2 (16·4-21·3)  28·5±1·3 (25·9-31·2) 9·7±1·5 6.570 0.000 3.728 0.000 
  5. Respiration 10 9·5±0·2 (9·08-9·92) 9·7±0·2 (9·36-10·04) 0·2±0·1 1.453 0.163 1.414 0.157 
  6. Bladder 15 4·6±0·8 (2·92-6·38) 9·8±1·0 (7·70-11·80) 5·1±1·0 4.972 0.000 3.218 0.001 
  7. Bowel 10 3·8±0·6 (2·53-5·07) 7·2±0·4 (6·27-8·13) 3·4±0·8 4.363 0.000 3.142 0.002 
  8. Toilet 5 0·9±0·3 (0·33-1·47) 1·9±0·4 (1·11-2·69) 1·0±0·3 2.874 0.010 2.553 0.011 
SCIM Mobility R & T 10 4·5±0·8 (2·99-6·10) 7·6±0·8 (5·87-9·33) 3·1±0·6 5.431 0.000 3.755 0.000 
  9. Bed mobility 5 2·8±0·5 (1·69-3·91) 4·8±0·5 (3·82-5·78) 2·0±0·4 4.873 0.000 3.256 0.001 
  10. Bed Wheelchair 2 0·9±0·2 (0·56-1·34) 1·5±0·2 (1·03-1·87) 0·5±0·2 3.249 0.004 2.640 0.008 
  11. Wheelchair Toilet 2 0·8±0·1 (0·45-1·05) 1·4±0·2 (0·91-1·79) 0·6±0·1 4.485 0.000 3.207 0.001 
SCIM Mobility I & O 30 5·8±0·7 (4·44-7·16) 9·0±0·9 (7·04-10·96) 3·2±0·7 4.913 0.000 3.398 0.001 
  12. Indoors 8 1·9±0·2 (1·53-2·27) 2·7±0·3 (2·15-3·25) 0·8±0·2 3.559 0.002 2.805 0.005 
  13. Moderate (≤100m) 8 1·9±0·2 (1·44-2·26) 2·7±0·3 (2·11-3·29) 0·9±0·2 3.489 0.002 2.853 0.004 
  14. Outdoors (>100m) 8 1·6±0·2 (1·21-2·09) 1·9±0·2 (1·47-2·33) 0·3±0·1 2.032 0.056 1.890 0.059 
  15. Stair Management 3 0 0 0   0.000 1.000 
  16. Wheelchair-car 2 0·3±0·1 (-0·01-0·51) 0·9±0·2 (0·47-1·33) 0·7±0·2 3.577 0.002 2.739 0.006 
  17. Ground-wheelchair 1 0·2±0·1 (-0·02-2·09) 0·8±0·3 (0·18-1·42) 0·7±0·3 2.156 0.044 2.714 0.007 
SCIM Mobility All 40 10·3±1·3 (7·63-12·97) 16·6±1·6 (13·3-19·9) 6·3±0·9 6.779 0.000 3.789 0.000 
Explanation. R & S refers to respiration and sphincters, R & T refers to room and toilet, I & O refers to indoor and outdoors.  W0 is 
week 0 or baseline score while W48 represents 41-87w mean scores ± sem with 95% confidence interval (CI 95%).  Δ is the 
difference (mean ± sem) between W0 and W48 scores.  We used Paired Samples T-Test and Wilcoxon Signed Ranks Test to 
compare findings at W0 and W48. 
